December 27, 2017 Regulatory LIDDS: NanoZolid® with immune-stimulating agent demonstrates significant efficacy
July 20, 2017 Regulatory LIDDS: LIDDS and Recipharm establish industrial manufacturing capabilities for a novel prostate cancer product
March 28, 2017 Regulatory LIDDS patenting pharmaceutical products with large biomolecules in NanoZolid® for immunotherapy
January 23, 2017 Regulatory LIDDS: Clear effects for local tumour treatment of lung cancer – promising preclinical results with NanoZolid® and cytostatics are to be published